PIK3CA and ovarian carcinoma: The rationale for using these drugs comes from evidence that a combination therapy with metformin and LY294002, an inhibitor of PI3K, reduces growth and induces apoptosis in ovarian cancer cells [237] by inhibiting PI3K/AKT and mTOR [238] while activating the AMPK/ACC pathway.